Transjugular intrahepatic portosystemic shunt: An overview
Harjit K. Bhogal, Arun J. Sanyal – 9 November 2012 – Watch a video presentation of this article
Transjugular intrahepatic portosystemic shunt: An overview
Harjit K. Bhogal, Arun J. Sanyal – 9 November 2012 – Watch a video presentation of this article
Drugs used in therapy of portal hypertension
Dhiraj Tripathi – 9 November 2012 – Watch the interview with the author
Donation after cardiac death liver transplantation: Another fly in the ointment
Neehar D. Parikh, Anton I. Skaro – 2 November 2012
PPARα activation in portal hypertension
Hongqun Liu, Samuel S. Lee – 31 October 2012
Cholesterol and nonalcoholic fatty liver disease: Renewed focus on an old villain
Thomas A. Kerr, Nicholas O. Davidson – 31 October 2012
Reply:
Naoki Tanaka, Frank J. Gonzalez – 31 October 2012
HCC Is promoted by bacterial translocation and TLR‐4 signaling: A new paradigm for chemoprevention and management
Sara Toffanin, Helena Cornella, Andrew Harrington, Josep M. Llovet – 31 October 2012
Reply:
Gyongyi Szabo, Shashi Bala – 30 October 2012
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies
Austin Duffy, Julia Wilkerson, Tim F. Greten – 30 October 2012 – The presence of cirrhosis increases the potential risk of hemorrhage for patients with hepatocellular carcinoma (HCC). We evaluated the relative risk for hemorrhage in patients with HCC treated with antiangiogenic agents. We performed a systematic review and meta‐analysis of antiangiogenic studies in HCC from 1995 to 2011. For nonrandomized studies we compared bleeding risk with other HCC single‐arm studies that did not include an antiangiogenic agent.